EU-OPENSCREEN ERIC is a non-profit research infrastructure, which operates on a global scale. We are funded by European countries (currently Czech Republic, Denmark, Finland, Latvia, Norway, Poland, Spain with Germany as host country) and offer access to academic high-throughput screening facilities and medicinal chemistry groups in these countries. Scientists from academia and industry can implement their screening projects at EU-OPENSCREEN´s partner laboratories using our general purpose diversity compound collection, the European Chemical Biology Library (ECBL), which is composed of 100.000 commercial compounds plus a growing number of compounds collected from academic chemistry groups. Hit optimisation can be done at our medicinal chemistry sites. All compounds will be profiled in a panel of about 20 assays, which will deliver extensive information on physico-chemical, cellular toxicity and anti-microbial properties.
Compound structures and primary screening data will be made public in the European Chemical Biology Database (ECBD), with the possibility to request an embargo period of up to three years to allow for data deposition after submitting a patent application or concurrently with the relaease of the scientific manuscript.
Progressing the discovery of biologically active substances in all areas of the life sciences by providing open access to the most advanced technologies, chemical and biological resources, and expertise. Harnessing the rich chemical knowledge of Europe by creating a common compound collection to advance the elucidation of the molecular mechanisms of complex biological phenomena.
EU-OPENSCREEN will become the premier European technology and expertise platform for chemical biology and the first stop for any academic researcher in the life sciences interested in developing specific chemical tools for their protein of interest.
Scientific excellence: Our first priority is to strive for scientific excellence in all our offerings and procedures.
Transparency: We are clear to our partners on how we choose and distribute projects, and our open access model requires the publication of all research data so that important results can be reproduced by others in the field.
Equality: We value equality as a crucial part of our work ethic because we always wish to make sure to treat our network of partners the same way.
ERICs are legal entities based on the COUNCIL REGULATION (EC) No 723/2009 of 25 June 2009 (Weblink). They are set-up by the European Commission upon request by a Member State and at least two other countries that are either Member States or associated countries. The aim of an ERIC is the establishment and operation of pan-European Research Infrastructures which can be either single-sited or distributed.
ERICs represent an added-value in the development of the European Research Area (ERA) and a significant improvement in the relevant scientific and technological fields. ERICs grant effective access to the European research community and the infrastructural facilities created and maintained by them. They contribute to the mobility of knowledge and/or researchers within the ERA and to the dissemination and optimisation of the results of research and development initiative.
ESFRI, the European Strategy Forum on Research Infrastructures, is a strategic instrument to develop the scientific integration of Europe and to strengthen its international outreach. The competitive and open access to high quality research infrastructures supports and benchmarks the quality of the activities of European scientists, and attracts the best researchers from around the world. ESFRI operates at the forefront of European and global science policies and contributes to its development, translating political objectives into concrete advice for RI in Europe.
EU-OPENSCREEN ERIC is part of the European Research Infrastructure landscape and member of the Life-Science Research Infrastructure LS RI cluster.
By making high-quality facilities, resources and services available to every scientist, research infrastructures ensure that science is driven by excellence through collaboration and not by the research capacity of individual countries, economic sectors, or institutions.
For more information on the benefits of European Life Science research infrastructures please visit the LS RI webpage or watch the introductory video on the benefits of collaborating with LS RIs, which also showcases successful EU-OPENSCREEN user projects: